AZD-9742(AZD-9742) - 药物靶点：Bacterial DNA gyrase x Bacterial top IV_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

Bacterial DNA gyrase x Bacterial top IV

作用机制

细菌DNA旋转酶复合体抑制剂、Bacterial top IV抑制剂(细菌拓扑异构酶IV抑制剂)

治疗领域-

在研适应症-

非在研适应症-

原研机构

阿斯利康制药有限公司

在研机构-

非在研机构

AstraZeneca PLC

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C25H26FN5O3

InChIKeyJYJKOWWSKTWAJA-RTWAWAEBSA-N

CAS号1033748-95-6

关联

6

项与 AZD-9742 相关的临床试验

NCT01275781 / Withdrawn临床1期

A Phase 1, Open-Label, Non-randomized, Single-Center Study to Assess Distribution, Metabolism and Excretion After [14C]-Labelled Intravenous Administration of AZD9742 as a 2-hour Infusion to Healthy Male Volunteers

The purpose of this study is to assess distribution, metabolism, and excretion of radio-labelled AZD9742 administered as a 2-hour infusion to healthy male volunteers.

开始日期2011-01-01

申办/合作机构

AstraZeneca PLC

NCT01154621 / Completed临床1期

A Phase I, Double-blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability, and Pharmacokinetics of a Single Dose of AZD9742 in Healthy Elderly Male and Female Volunteers

The aim of this study is to examine the safety and tolerability of a single dose of AZD9742 in elderly individuals.

开始日期2010-06-01

申办/合作机构

AstraZeneca PLC

NCT01124760 / Completed临床1期

A Phase I, Single Center, Open Label, 2-consecutive-group, 2-period, 1-sequence Crossover Study to Assess the Effect of Diltiazem (Cardizem), a Moderate CYP3A4 Inhibitor, or Ketoconazole, a Potent CYP3A4 Inhibitor, on the Pharmacokinetics of a Single Intravenous Dose of 150mg of AZD9742.

The aim of this study is to examine the effect of coadministration of CYP3A4 inhibitors on the pharmacokinetics of AZD9742.

开始日期2010-05-01

申办/合作机构

AstraZeneca PLC

100 项与 AZD-9742 相关的临床结果

登录后查看更多信息

100 项与 AZD-9742 相关的转化医学

登录后查看更多信息

100 项与 AZD-9742 相关的专利（医药）

登录后查看更多信息

100 项与 AZD-9742 相关的药物交易

登录后查看更多信息